Search research articles
Contact Us
Filters
Showing results (11-20 of 15) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 15 results.
European Journal of Cancer (Oxford, England : 1990)
|
October 10, 2022
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2021
Reply to T. Shimoi et al and Y. Shimanuki et al
Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Cancer
|
January 18, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, et al.
JCO Oncology Advances
|
May 18, 2026
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial
Moriah Forster, Fengmin Zhao, Sarah Bell, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 15) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 15 results.
European Journal of Cancer (Oxford, England : 1990)
|
October 10, 2022
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2021
Reply to T. Shimoi et al and Y. Shimanuki et al
Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Cancer
|
January 18, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, et al.
JCO Oncology Advances
|
May 18, 2026
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial
Moriah Forster, Fengmin Zhao, Sarah Bell, et al.
Page
of 2